AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18385391
Drug: Niacinamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacinamide (500 to 1500 mg/d) among compliant patients
Trial: 12915954
Drug: Menthol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthol (100 mg)
Trial: 9137841
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake blockers
Trial: 8212819
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of B-WC vaccine at 7, 14, or 28-42 day intervals
Trial: 8212819
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of B-WC vaccine at 3-day intervals
Trial: 8212819
Drug: Different time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different time intervals tested (3-42 days) for vibriocidal antibody responses
Trial: 8212819
Drug: B-WC vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-WC vaccine with sodium bicarbonate powder
Trial: 3940333
Drug: Gentle breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentle breast stimulation for 1.5 hours in hospital and then for three hours daily for three days at home.
Trial: 31996978
Drug: FV+ (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FV+ (standard food parcel plus the recommended daily amount of fruit and vegetables)
Trial: 31996978
Drug: Snacks-+FV+ (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snacks-+FV+ (standard food parcel with replacement of unhealthy snacks by staple foods plus the recommended daily amount of fruit and vegetables)
Trial: 27833172
Drug: Cranberry supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry supplementation (1500 mg cranberry fruit powder for a mean of 30 days)
Trial: 10485720
Drug: Nevirapine 200
RxNorm normalized name: nevirapine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine 200 mg orally at onset of labour and 2 mg/kg to babies within 72 h of birth
Trial: 10485720
Drug: Zidovudine 600
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 600 mg orally to the mother at onset of labour and 300 mg every 3 h until delivery, and 4 mg/kg orally twice daily to babies for 7 days after birth
Trial: 6128282
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pseudoephedrine and triprolidine administered every 6 hours
Trial: 24290597
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (600 mg of elemental Ca/d as CaCO3)
Trial: 8841863
Drug: Continuous thoracic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous thoracic paravertebral infusion of bupivacaine (loading dose of 15 mL of 0.375% bupivacaine, plus an infusion of 5 mL of 0.25% bupivacaine every hour)
Trial: 8841863
Drug: Bolus regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus regimen of 20 mL of 0.375% bupivacaine every 6 hours
Trial: 1536215
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg micronized 17 beta-estradiol
Trial: 1536215
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg micronized 17 beta-estradiol
Trial: 1536215
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg micronized 17 beta-estradiol
Trial: 1536215
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg micronized 17 beta-estradiol (after double-blind phase)
Trial: 6369979
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral nonabsorbable antibiotics
Trial: 31008751
Drug: Dexmedetomidine 0
RxNorm normalized name: dexmedetomidine 0.12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0 µg/kg (control)
Trial: 24616335
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg) or Amlodipine (5 mg)
Trial: 24616335
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy (Aliskiren + Hydrochlorothiazide or Amlodipine)
Trial: 22081150
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg bevacizumab
Trial: 17203360
Drug: Chronic use
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic use of antibiotics
Trial: 9370765
Drug: Oral resources
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral resources
Trial: 22795164
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 10mg/kg dexamethasone intravenously at the beginning of the operation and 24 hours after (Group II)
Trial: 22795164
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 10mg/kg dexamethasone intravenously at the beginning of the operation, before osteotomy, and 24 hours after (Group III)
Trial: 18206133
Drug: Myofeedback training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofeedback training in combination with ergonomic counselling (Mfb/EC)
Trial: 16897249
Drug: Neurotropin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotropin (3 ml) combined with saline (3 ml)
Trial: 16897249
Drug: 1% Mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Mepivacaine (6 ml)
Trial: 10954955
Drug: Cefdinir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir (300 mg twice daily for 5 days)
Trial: 10954955
Drug: Loracarbef (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loracarbef (400 mg twice daily for 7 days)
Trial: 8769695
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydroxyurea and interferon alpha
Trial: 1376577
Drug: Ampicillin/Metronidazole combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin/Metronidazole combination
Trial: 29570512
Drug: Effervescent paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent paracetamol (1 g three times a day)
Trial: 29570512
Drug: Noneffervescent paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noneffervescent paracetamol
Trial: 29570512
Drug: Effervescent paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent paracetamol
Trial: 20466589
Drug: Pregabalin 50
RxNorm normalized name: pregabalin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 50 mg/day
Trial: 20466589
Drug: Pregabalin 100
RxNorm normalized name: pregabalin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 100 mg/day
Trial: 18603250
Drug: Intrauterine instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine instillation of 5 mL of 1% lignocaine 2 minutes prior to the procedure
Trial: 18603250
Drug: Oral naproxen
RxNorm normalized name: naproxen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naproxen 375 mg self-administered 1 hour prior to HSG
Trial: 16160876
Drug: SR bupropion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR bupropion (300 mg/day)
Trial: 11693589
Drug: Child training
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child training treatment group (CT) utilizing the Incredible Years Dinosaur Social Skills and Problem Solving Curriculum
Trial: 11693589
Drug: Child training
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child training treatment group (CT)
Trial: 8116059
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin A
Trial: 3553455
Drug: Antibiotics (cefazolin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (cefazolin and gentamicin) administered in the immediate preoperative and intraoperative periods
Trial: 3553455
Drug: Antibiotics (cefazolin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (cefazolin and gentamicin)
Trial: 30160499
Drug: Low risk
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low risk drinking during treatment
Trial: 30160499
Drug: Mostly abstinent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mostly abstinent during treatment
Trial: 30160499
Drug: Heavy drinking
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy drinking during treatment
Trial: 24906406
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy delivered by healthcare assistants
Trial: 21287460
Drug: 0.5% nifedipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% nifedipine cream for 4 weeks
Trial: 21287460
Drug: Stool softeners
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stool softeners and 2% lidocaine cream for 4 weeks
Trial: 10710823
Drug: New Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Cyclosporine A microemulsion formulation
Trial: 2117054
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (GTN patches)
Trial: 30836807
Drug: HBOT (20‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOT (20‐40 sessions) plus conventional treatment
Trial: 22537541
Drug: Hypofractionation (62
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionation (62 Gy at 3.1 Gy per fraction in 5 weeks) + 9-month androgen deprivation therapy
Trial: 22537541
Drug: Conventional fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionation (80 Gy at 2 Gy per fraction in 8 weeks) + 9-month androgen deprivation therapy
Trial: 16446682
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (5 g creatine monohydrate, 4 times daily for 6 days)
Trial: 11081314
Drug: Aldactone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldactone (200 mg i.v.)
Trial: 11081314
Drug: Furosemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (20 mg i.v.)
Trial: 8671857
Drug: CsA (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA (7.5 mg/kg. b.i.d. in olive oil)
Trial: 4096205
Drug: 1% pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% pilocarpine solution with nasolacrimal obstruction (NLO)
Trial: 4096205
Drug: 1% pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% pilocarpine solution with eyelid closure (EC)
Trial: 4096205
Drug: 1% pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% pilocarpine solution with both NLO and EC
Trial: 4096205
Drug: 1% pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% pilocarpine solution with neither NLO nor EC
Trial: 4096205
Drug: 3% pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% pilocarpine ointment
Trial: 4096205
Drug: 1% pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% pilocarpine solution
Trial: 30907209
Drug: 600 µg
RxNorm normalized name: P.G. 600 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 µg of misoprostol (oral or vaginal)
Trial: 30907209
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 mg vitamin B6)
Trial: 26813359
Drug: PEGylated human
RxNorm normalized name: Pegylated human c-peptide
DrugBank: Pegylated synthetic human c-peptide (DB16283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGylated human recombinant hyaluronidase (PEGPH20) at doses of 1.0 μg/kg (n = 4), 1.6 μg/kg (n = 4), or 3.0 μg/kg (n = 20) in combination with gemcitabine (Gem)
Trial: 26813359
Drug: PEGPH20 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGPH20 in combination with Gem for patients with high hyaluronan (HA) levels
Trial: 26813359
Drug: PEGPH20 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGPH20 in combination with Gem for patients with low hyaluronan (HA) levels
Trial: 9825371
Drug: i.v. propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. propafenone (PFN) (2 mg/kg bolus followed by 0.0078 mg/kg/min infusion)
Trial: 9825371
Drug: o.s. propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: o.s. propafenone (PFN) (600 mg)
Trial: 2681717
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin (anti-embolism stockings)
Trial: 1090708
Drug: Major tranquilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Major tranquilizer (neuroleptic) treatment
Trial: 1090708
Drug: Therapy resistant
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy resistant schizophrenic patients
Trial: 29363217
Drug: Oxycodone 15
RxNorm normalized name: oxyCODONE 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 15 mg
Trial: 27509214
Drug: L-PRF socket
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRF socket filling
Trial: 25362008
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg/5 mL elemental zinc as zinc sulfate) for 2 weeks
Trial: 25362008
Drug: Placebo (syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (syrup base) for 2 weeks
Trial: 22674156
Drug: Intravenous butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous butorphanol (1 mg loading dose followed by 0.2 mg/h infusion)
Trial: 22674156
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline (infusion of the same volume)
Trial: 20299607
Drug: Eplerenone 50
RxNorm normalized name: eplerenone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 50 mg/d
Trial: 12675179
Drug: Vecuronium bromide
RxNorm normalized name: Vecuronium Bromide
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vecuronium bromide (0.015 mg/kg) followed by repeat dose (0.08 mg/kg) at peak D1 suppression
Trial: 12675179
Drug: Vecuronium bromide
RxNorm normalized name: Vecuronium Bromide
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vecuronium bromide (0.08 mg/kg) at peak DBS ratio suppression
Trial: 10326708
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity training (30 minutes daily biking on an ergometer in supine position)
Trial: 27899400
Drug: Sertraline (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (titrated up to a maximum of 100 mg daily over 28 days)
Trial: 25099071
Drug: Yogurt drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt drink with added plant stanol esters (4 g)
Trial: 9658375
Drug: Combined hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hepatitis A/hepatitis B vaccine (3 injections at 0, 1, and 6 months)
Trial: 8017413
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg immediate-release lithium carbonate tablets (Lithotab)
Trial: 8017413
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg extended-release lithium carbonate tablets (Eskalith CR)
Trial: 8017413
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg extended-release lithium carbonate tablets (Lithobid)
Trial: 162924
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytosine arabinoside (3 mg/kg every 24 hr for up to 7 days)
Trial: 19446144
Drug: Lidocaine patch
RxNorm normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patch applied to the trigger point for 4 days (total daily dose, 350 mg)
Trial: 19446144
Drug: Infiltration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration of the trigger point with two 1-mL injections of 0.5% bupivacaine hydrochloride given 2 days apart
Trial: 19446144
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch applied to the trigger point for 4 days
Trial: 17308963
Drug: Reviparin (Clivarin)
RxNorm normalized name: reviparin
DrugBank: Reviparin (DB09259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reviparin (Clivarin) 3,436 IU anti-Xa/0.6 ml, self-administered twice daily for 8 weeks
Trial: 15111849
Drug: Dacron patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacron patch (Hemashield Finesse) closure
Trial: 10389549
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) 200 micrograms
Trial: 1739321
Drug: Intensive individual
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive individual speech therapy
Trial: 1739321
Drug: Weekly speech
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly speech therapy
Trial: 23708466
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50 or 70 mg
Trial: 15671215
Drug: Oral L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-arginine (12 g/d for 3 wk)
Trial: 12509647
Drug: Zincum gluconicum
RxNorm normalized name: Zincum Gluconicum 1 X Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zincum gluconicum nasal gel (33 mmol/l), administered four times daily until symptoms resolved, for a maximum of 10 days.
Trial: 12509647
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal gel, administered four times daily until symptoms resolved, for a maximum of 10 days.
Trial: 12509647
Drug: Zincum gluconicum
RxNorm normalized name: Zincum Gluconicum 1 X Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zincum gluconicum nasal gel
Trial: 12509647
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal gel
Trial: 1642912
Drug: Inhalation technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation technique (propofol and alfentanil followed by nitrous oxide and isoflurane)
Trial: 6443759
Drug: Piroxicam (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (40 mg for the first 2 days, then 20 mg daily)
Trial: 29878617
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injections (n=45)
Trial: 29878617
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) injections (n=44)
Trial: 25252255
Drug: Sealed in-office
RxNorm normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealed in-office bleaching technique using 35% hydrogen peroxide gel for a single 45-min application.
Trial: 25252255
Drug: Conventional in-office
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional in-office bleaching technique using 35% hydrogen peroxide gel for a single 45-min application.
Trial: 23249399
Drug: Group psychoeducational
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group psychoeducational program (12 weekly sessions of 1.5 hours each led by two nurses)
Trial: 14583178
Drug: Aldose reductase
RxNorm normalized name: Aldose reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldose reductase inhibitor (ARI); administration details not specified
Trial: 9987171
Drug: Hepagene vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepagene vaccine (5, 10, 20, and 40 micrograms/ml)
Trial: 9987171
Drug: Hepagene vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepagene vaccine (5 micrograms/ml)
Trial: 9987171
Drug: Hepagene vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepagene vaccine (10 micrograms/ml or more)
Trial: 9987171
Drug: Repeated 'S'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated 'S' containing vaccines
Trial: 8341891
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methamphetamine (40-60 mg)
Trial: 8341891
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methamphetamine (20 mg)
Trial: 8341891
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (5 or 10 mg methamphetamine)